

Newron Pharmaceuticals Meets “the Street”



CHALLENGE


- Build credibility and visibility in the investment community for a company focused in central nervous system disorder
- Develop program to build foundation in advance of U.S. listing

LHS SOLUTION

- Utilized LHS Reach™ to target U.S. investment community
- Reposition company as near-term commercial opportunity and long-term pipeline
- Build awareness and through media and investor introductions

RESULTS

- Increased awareness of corporate profile and understanding of company’s value proposition
- Coordinated more than 30 high-value one-on-one meetings with investors; on-going
- Invitations to present at 5 conferences within 1 year
- Secured coverage by leading analyst
- Placed CEO OpEd in *Life Science Leader*



COMPANY NOTE
March 9, 2016

Newron Pharma. (NWRN SW) **Overweight**

Safinamide - New Park's Drug Points to New Paradigm & Emerging Pipeline Value

Jefferies



June 7-10, 2016
New York City



REALIZE THE POWER OF PARTNERSHIP.

The 28th Annual Healthcare Conference

November 29-30, 2016 in New York City



Newron Pharmaceuticals to Present at the 27th Annual ROTH Conference

ROTH Conference 2015

March 04, 2015 08:30 AM Eastern Standard Time

MILAN, Italy--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ("Newron") [Ticker: SIX: NWRN], a research and development company focused on novel central nervous system (CNS) and pain therapies, today announced that Ravi Anand, M.D., Chief Medical Officer, will provide a corporate update at the 27th Annual ROTH Conference on Tuesday, March 10, 2015, at 9:00 a.m. PT. The conference will be held at the Ritz Carlton in Laguna Niguel, CA.



Recognizing the most innovative companies
at the 2016 BIO Investor Forum

SUPPORTED BY **BioCentury**